# Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients

> **NIH NIH R01** · BRIGHAM AND WOMEN'S HOSPITAL · 2021 · $686,566

## Abstract

Prostate cancer is the 2nd most common form of cancer among men in United States, in fact, over 26,000 men will
die from PCa in the US in 2017. Researchers now believe that prostate cancer specific progression to death can be
altered by a more optimal initial treatment strategy that includes systemic treatment. However, there is a paucity of
material and research available to optimize the sequence or optimal combination(s) of agents and to maximize the
impact of neoadjuvant treatment tailored specifically to the individual patient. This issue is heightened by the recent
introduction of new drugs for androgen deprivation, chemotherapy and more recently, targeted therapy of high-risk
prostate cancer (PCa). Our long-term goal is to develop an innovative treatment regimen for men with high-risk PCa
to treat occult metastatic disease as well as the local tumor, by utilizing neoadjuvant therapy. The objective of this
project is to assess the feasibility of implantable microdevices (IMD) to measure local intratumor response to multiple
agents. The rationale of the study is that, upon successful completion of this study, we will have shown that we can
obtain intratumor efficacy readouts for 19 therapies from a single patient. We will also have established whether these
measurements can be used to tailor personalized and specific systemic therapy for a particular patient. With expertise
in bioengineering, imaging, pathology, oncology and urology, our team is well prepared to complete this research. We
will achieve our goals in the following four specific aims: 1) Develop and clinically validate a device to measure
intratumor response to multiple therapies without exposing patients to systemic toxicity; and 2) Demonstrate
differential local tumor response to different drugs delivered by IMD; and 3) Examine the role of biomarkers in the
treatment response; and 4) To retrieve implanted IMD under MRI guidance using a retrieval device. The proposed
research is significant since each tumor responds differently to different agents and lays the foundation for an IMD
directed neoadjuvant trial. This will lay the ground work to prove that local intratumor response to micro doses of
multiple agents can be used to effectively screen for and tailor the optimal treatment in a novel neo-adjuvant regimen.
In addition, by examining the tumor for genetic and physiologic changes, we will be able to in vivo correlate potential
biomarkers of tumor response to multiple drugs. Our approach is innovative as the assessment of response occurs
within the patient native tumor environment - as such stroma and systemic immune response can be assessed. We
will leverage expertise in a precision image guided approach to achieve precise implantation of IMDs into prostate
tumors under MRI guidance, and subsequent retrieval during planned surgery.

## Key facts

- **NIH application ID:** 10172872
- **Project number:** 5R01CA232174-03
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** Nobuhiko Hata
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $686,566
- **Award type:** 5
- **Project period:** 2019-03-04 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10172872

## Citation

> US National Institutes of Health, RePORTER application 10172872, Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients (5R01CA232174-03). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10172872. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*